US SEC Trading Suspension Halt Orders — July 17, 2026

Stockholders' equity fell below $2.5M as of March 31, 2026, failing the primary and alternative listing standards (MVLS <$35M, net income <$500K). No insider buying or capital allocation actions reported. Hearing request may temporarily stay delisting, but no assurance of success.

MVLS has been below $50M since June 1, 2026, with a 180-day cure period until January 11, 2027. No insider transactions or capital allocation activity reported. Failure to regain compliance could lead to delisting or transfer to Nasdaq Capital Market.

Common stock bid price remained below $1.00 for 30 consecutive business days. Must cure by January 11, 2027, or face delisting. Critical risk: if stock trades at or below $0.10 for ten consecutive days, Nasdaq will immediately delist without any compliance period. No insider buying or capital allocation reported.

Staff Delisting Determination received on July 15, 2026, for failing $2.5M stockholders' equity requirement (reported $2,091,324). Compliance plan denied due to lack of definitive PIPE financing agreement. Trading suspension scheduled for July 24, 2026, if no hearing request by July 22, 2026. No insider buying or capital allocation reported.

Zero insider buying activity across all filings, indicating management has no confidence in reversing the delisting risks. Combined with no dividends or buybacks, this signals severe financial distress and potential total equity loss.

Both failed the same $2.5M stockholders' equity threshold, but Caring Brands is further along in the process (staff determination issued, compliance plan denied) and faces an imminent suspension deadline, making it the higher-risk of the two.

The $0.10 immediate delisting trigger is the most punitive among the four filings. If the stock price continues to decline, it could be delisted without any cure period, creating a binary risk for shareholders.

Has the longest cure period (180 days until January 11, 2027) and the option to transfer to Nasdaq Capital Market, providing more flexibility than the others. However, no insider buying or capital allocation actions suggest limited confidence in a turnaround. [NEUTRAL/BEARISH]

Trading will be suspended at the open on July 24, 2026, if no hearing request is filed by 4:00 PM ET on July 22, 2026. This is the most time-sensitive risk across all filings, with only 5 days to act.

If the stock trades at or below $0.10 for ten consecutive days, Nasdaq will immediately delist without any compliance period. This creates a cliff risk for shareholders if the price continues to decline.

Stockholders' equity fell below $2.5M as of March 31, 2026, and the company also failed alternative standards (MVLS <$35M, net income <$500K). No insider buying or capital allocation reported, indicating no internal confidence in a recovery.

MVLS has been below $50M since June 1, 2026, with no insider buying or capital allocation activity. If not cured by January 11, 2027, delisting or transfer to Nasdaq Capital Market is likely.

Zero insider purchases reported across all filings, while three of four companies have CEOs or CFOs who could have bought shares. This uniform absence of insider confidence is a strong negative signal.

The compliance plan was denied because the company had not entered a definitive agreement for additional PIPE financing, indicating that external funding sources have not materialized.

No dividends, buybacks, or other shareholder returns reported across any filing, consistent with companies conserving cash to survive rather than rewarding shareholders.

The company must complete any reverse stock split no later than 10 business days before the compliance period expires (January 11, 2027), unless eligible for an additional 180-day period. Reverse splits often lead to further price declines.

With a 180-day compliance period until January 11, 2027, and the option to transfer to Nasdaq Capital Market, Actuate has the most time and flexibility among the four companies. If the company can execute a reverse stock split or raise capital to boost MVLS, it could avoid delisting.

If Fold meets all other initial listing standards except the Minimum Bid Price Requirement and provides written notice of intent to cure, it may qualify for an additional 180-day compliance period, extending the timeline to mid-2027.

The company intends to request a hearing before a Nasdaq Hearing Panel, which will stay the suspension and delisting pending the Panel's decision and any extension period granted. This provides a temporary reprieve for management to present a compliance plan.

If the company submits a hearing request by July 22, 2026, trading will be temporarily stayed, buying time to secure PIPE financing or other funding. The deadline is tight but still actionable.

All four companies could potentially execute reverse stock splits to regain compliance with bid price or MVLS requirements, though this is often a short-term fix and can lead to further declines.

If Actuate cannot regain compliance on The Nasdaq Global Market, it may be eligible to transfer to the Nasdaq Capital Market, which has lower listing standards ($35M MVLS vs $50M). This could provide a path to continued listing.

The deficiency letter has no immediate effect on the listing of the common stock, which continues to trade on Nasdaq. This gives shareholders time to assess the company's plans before making decisions.

All four filings involve micro-cap companies (<$50M market cap) receiving delisting or non-compliance notices from Nasdaq within a three-day window (July 13-15, 2026). This suggests a coordinated enforcement push by Nasdaq against financially weak companies, potentially signaling a broader market trend of tightening listing standards. [IMPLICATION: Expect more delisting notices for micro-caps with weak balance sheets.]

Two of four companies (Dare Bioscience and Caring Brands) failed the same $2.5M stockholders' equity requirement, indicating that many micro-caps are struggling to maintain minimum equity levels in the current economic environment. [IMPLICATION: Investors should screen for companies with stockholders' equity near $2.5M as potential delisting candidates.]

Across all four filings, there were zero insider purchases, zero dividends, and zero buybacks reported. This uniform absence of insider and management confidence is a strong negative signal for the micro-cap sector, suggesting that even company insiders see limited hope for recovery. [IMPLICATION: Avoid micro-caps with no insider buying and no capital allocation activity.]

None of the four companies reported any dividends, buybacks, or other shareholder returns, consistent with companies in survival mode. This contrasts with larger-cap companies that often continue buybacks even during downturns. [IMPLICATION: Micro-cap investors should not expect any shareholder returns from distressed companies.]

The filings show a wide range of urgency: Caring Brands faces suspension in 5 days, while Actuate Therapeutics has 180 days to cure. This dispersion creates different risk profiles for investors, with Caring Brands being the most time-sensitive and Actuate offering the most flexibility. [IMPLICATION: Investors must differentiate between imminent suspension risks and longer-term compliance challenges.]

Watch for whether the company files a hearing request by 4:00 PM ET on July 22, 2026. If filed, trading will be temporarily stayed; if not, trading will be suspended at the open on July 24, 2026. [Date: July 22, 2026]

The company intends to request a hearing before a Nasdaq Hearing Panel. Watch for the hearing date and the Panel's decision on whether to grant a stay of delisting. [Date: TBD]

Monitor Fold Holdings' stock price for any sustained decline to $0.10 or below for ten consecutive days, which would trigger immediate delisting without any compliance period. [Date: Ongoing]

Watch for any announcements regarding actions to boost MVLS above $50M, such as reverse stock splits, capital raises, or business developments. The 180-day cure period ends January 11, 2027. [Date: January 11, 2027]

Any announcements of reverse stock splits should be monitored, as they are a common but often ineffective cure for bid price and MVLS non-compliance. [Date: Ongoing]

Watch for any definitive agreement for additional PIPE financing, which was the reason the compliance plan was denied. If secured, it could change the outlook. [Date: Ongoing]

Monitor whether additional delisting notices are issued to other micro-cap companies in the coming weeks, which would confirm a broader enforcement trend. [Date: Ongoing]

Watch for any announcement that Fold qualifies for an additional 180-day compliance period, which would extend the timeline to mid-2027. [Date: Before January 11, 2027]